Castle Biosciences (CSTL) Cash from Investing Activities (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Cash from Investing Activities data on file, last reported at -$25.8 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 15.03% year-over-year to -$25.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$63.7 million (down 20.56% YoY) and the FY2025 annual result came in at -$60.4 million, down 20.4% from the prior year.
• Cash from Investing Activities fell to -$25.8 million in Q1 2026 per CSTL's latest filing, from $8.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $16.6 million in Q1 2023, with the low at -$134.2 million in Q3 2022.
• Average Cash from Investing Activities over 5 years is -$18.8 million, with a median of -$15.4 million recorded in 2023.
• Year-over-year, Cash from Investing Activities tumbled 14434.13% in 2022 and surged 4225.37% in 2023.
• Castle Biosciences' Cash from Investing Activities stood at -$4.5 million in 2022, then tumbled by 71.17% to -$7.7 million in 2023, then jumped by 175.21% to $5.8 million in 2024, then surged by 53.05% to $8.8 million in 2025, then slumped by 392.19% to -$25.8 million in 2026.
• Business Quant data shows CSTL's Cash from Investing Activities at -$25.8 million in Q1 2026, $8.8 million in Q4 2025, and -$18.4 million in Q3 2025.